<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="doi: 10.1016/S1473-3099(20)30360-1 : Article Vaccine development during global epidemics: the" exact="Zika" post="experience CastanhaPriscila M SaMarquesErnesto T Amarques@pitt.edua[a], pmc-release: 2020-5-5epub: 2020-5-5(C)"/>
 <result pre="North and South American continents experienced a major epidemic of" exact="Zika" post="virus in 2015â€&quot;16, which infected up to 70% of"/>
 <result pre="to 70% of the population in some areas.1 Until then," exact="Zika" post="virus infection had been considered a benign viral infection"/>
 <result pre="consequences. However, during the 2015â€&quot;16 epidemic, it was recognised that" exact="Zika" post="virus infection can lead to neurological diseases of the"/>
 <result pre="characterised by microcephaly. The spectrum of clinical presentations of congenital" exact="Zika" post="syndrome is still not fully described. Studies have shown"/>
 <result pre="shown that about 20% of babies of mothers exposed to" exact="Zika" post="virus during pregnancy who were born with no initial"/>
 <result pre="cognitive development and other neurological abnormalities later in life.2, 3" exact="Zika" post="is endemic in all tropical areas of the world,"/>
 <result pre="of the global population lives in areas at risk of" exact="Zika" post="transmission, and the chance for future Zika epidemics remains"/>
 <result pre="at risk of Zika transmission, and the chance for future" exact="Zika" post="epidemics remains very real. 5 years after the 2015â€&quot;16"/>
 <result pre="the 2015â€&quot;16 outbreak, we still do not have a licensed" exact="Zika" post="vaccine despite substantial efforts throughout this time period.4 In"/>
 <result pre="1 clinical trial on the safety and immunogenicity of a" exact="Zika" post="purified inactivated virus vaccine given via standard, accelerated, or"/>
 <result pre="standard, accelerated, or shortened schedules. The authors showed that their" exact="Zika" post="vaccine formulation was well tolerated, immunogenic, and did not"/>
 <result pre="an accelerated schedule (weeks 0 and 2), elicited a robust" exact="Zika" post="virus neutralising antibody response that peaked 2 weeks after"/>
 <result pre="than 100 by study week 16. The sharp decay in" exact="Zika" post="virus neutralising antibody titres might be linked to poor"/>
 <result pre="an ideal vaccine, and efforts to develop or refine promising" exact="Zika" post="vaccine candidates must remain a priority. However, because of"/>
 <result pre="made we might be somewhat better prepared should a new" exact="Zika" post="outbreak occur. Despite low antibody durability after boost, it"/>
 <result pre="would allow for a quicker humoral immune response to a" exact="Zika" post="infection, as has been shown for other flavivirus vaccines.7,"/>
 <result pre="of dengue infection. Anti-dengue antibodies have been shown to enhance" exact="Zika" post="virus infection in in-vitro, ex-vivo, and animal models, but"/>
 <result pre="dengue.10 This potential risk could probably be mitigated by administering" exact="Zika" post="vaccine to individuals who have already been exposed to"/>
 <result pre="We have learned a lot from efforts to develop a" exact="Zika" post="vaccine, and the experience acquired during the Zika outbreak"/>
 <result pre="develop a Zika vaccine, and the experience acquired during the" exact="Zika" post="outbreak is reflected by the rapid response to the"/>
 <result pre="a sprint race, it is a marathon. Efforts to develop" exact="Zika" post="vaccines must continue to be supported financially if we"/>
 <result pre="future outbreaks. References References 1Rodriguez-BarraquerICostaFNascimentoEJMImpact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic regionScience363201960761030733412 2EinspielerCUtschFBrasilPAssociation of"/>
 <result pre="a dengue endemic regionScience363201960761030733412 2EinspielerCUtschFBrasilPAssociation of infants exposed to prenatal" exact="Zika" post="virus infection with their clinical, neurologic, and developmental status"/>
 <result pre="toolJAMA Netw Open22019e187235 3MulkeySBArroyave-WesselMPeytonCNeurodevelopmental abnormalities in children with in utero" exact="Zika" post="virus exposure without congenital Zika syndromeJAMA Pediatr2020published online Jan"/>
 <result pre="in children with in utero Zika virus exposure without congenital" exact="Zika" post="syndromeJAMA Pediatr2020published online Jan 6.10.1001/jamapediatrics.2019.5204 4PolandGAOvsyannikovaIGKennedyRBZika vaccine development: current"/>
 <result pre="development: current statusMayo Clin Proc9420192572258631806107 5StephensonKETanCSWalshSRSafety and immunogenicity of a" exact="Zika" post="purified inactivated virus vaccine given via standard, accelerated, or"/>
 <result pre="NgonoAYoungMPBunzMCD4+ T cells promote humoral immunity and viral control during" exact="Zika" post="virus infectionPLoS Pathog152019e1007474 7CapedingMRAlbertoERBouckenoogheAFive-year antibody persistence following a Japanese"/>
 <result pre="IC51Vaccine2820105197C202 9LangerakTMumtazNTolkVIThe possible role of cross-reactive dengue virus antibodies in" exact="Zika" post="virus pathogenesisPLoS Pathog152019e1007640 10CastanhaPMSErdosGWatkinsSCFaloLDMarquesETABarratt-BoyesSMReciprocal immune enhancement of dengue and"/>
 <result pre="Zika virus pathogenesisPLoS Pathog152019e1007640 10CastanhaPMSErdosGWatkinsSCFaloLDMarquesETABarratt-BoyesSMReciprocal immune enhancement of dengue and" exact="Zika" post="virus infection in human skinJCI insight52020133653 We declare no"/>
</results>
